Search

CN-121971626-A - Use of Jiao Kongsu D antibodies and inhibitors thereof in the preparation of products for preventing or treating myopia

CN121971626ACN 121971626 ACN121971626 ACN 121971626ACN-121971626-A

Abstract

The invention relates to the field of biological medicine, in particular to Jiao Kongsu D antibody and application of an inhibitor thereof in preparing a product for preventing or treating myopia. The present invention provides prevention or treatment of myopia with Jiao Kongsu D (GASDERMIN D, GSDMD) antibodies, or inhibitors thereof, which experiments indicate that inhibition GSDMD inhibits increases in ocular axis length and diopter and alleviates increases in ocular axis length and diopter caused by GSDMD overexpression. The invention provides an explanation of pathogenesis of myopia and provides a scheme for precisely targeting myopia treatment.

Inventors

  • LI YUJUAN

Assignees

  • 山东中医药大学

Dates

Publication Date
20260505
Application Date
20260331

Claims (10)

  1. 1. Use of Jiao Kongsu D as a target in the manufacture of a product for preventing or treating myopia.
  2. 2. The use of claim 1, wherein the product: (i) Inhibit, reduce or eliminate pyroxylin D, or (Ii) Down-regulating or silencing Jiao Kongsu D gene expression.
  3. 3. The use of claim 1, wherein the product comprises Jiao Kongsu D antibody or a pyroxylin D inhibitor.
  4. 4. The use of claim 3, wherein the Jiao Kongsu D antibody comprises an antibody that inhibits Jiao Kongsu D.
  5. 5. The use of claim 3, wherein the Jiao Kongsu D inhibitor comprises Necrosulfonamide.
  6. 6. The use according to claim 1, wherein the product comprises a medicament, an agent or a vaccine.
  7. 7. The use according to claim 6, wherein the medicament comprises a pharmaceutical excipient selected from at least one of diluents, excipients, flavoring agents, sweeteners.
  8. 8. The method for constructing the myopia model is characterized by comprising the step of constructing based on over-expression Jiao Kongsu D.
  9. 9. The method of construction of claim 8, comprising: s1, constructing adeno-associated virus expressing Jiao Kongsu D; s2, administering the adeno-associated virus to an experimental animal.
  10. 10. The construction method according to claim 8 or 9, wherein the coding gene sequence of Jiao Kongsu D is shown in SEQ ID No. 1.

Description

Use of Jiao Kongsu D antibodies and inhibitors thereof in the preparation of products for preventing or treating myopia Technical Field The invention relates to the field of biological medicine, in particular to Jiao Kongsu D (GASDERMIN D, GSDMD) protein and application of an inhibitor thereof in preparation of a product for preventing or treating myopia. Background The vision health situation is extremely severe, and myopia has become a major public health problem. In the research field of myopia prevention and control, the existing clinical intervention means still have obvious defects. Evidence-based medical research proves that although intervention means such as cornea shaping lenses, low-concentration atropine, novel optical design lenses and the like can effectively relieve myopia process, the actual coverage rate is lower due to medical resource allocation and patient compliance difference. In the aspect of pathological mechanism research, although the theory of myopic etiology such as abnormal secretion of retina dopamine, choroidal ischemia, scleral hypoxia and superplastic change is proved, the cascade control mechanism of a signal path is still unclear, and accurate targeted treatment is restricted. The above-mentioned current situation highlights the urgent need for new strategies for myopia intervention, and there is a need to search for new therapeutic strategies from a mechanistic point of view. Disclosure of Invention Accordingly, the present invention is directed to the use of a pyroxylin D antibody and inhibitors thereof in the preparation of a product for preventing or treating myopia. In order to achieve the above object, the present invention provides the following technical solutions. The invention provides an application of Jiao Kongsu D serving as a target in preventing or treating myopia. In some embodiments of the invention, the above-described use prevents or treats myopia by any of: (i) Inhibit, reduce or eliminate Jiao Kongsu D protein expression in the eye, or (Ii) Down-regulate or silence the eye Jiao Kongsu D gene. The invention also provides an application of Jiao Kongsu D serving as a target point in preparing a product for preventing or treating myopia. In some embodiments of the invention, the product of the above application: (i) Inhibit, reduce or clear Jiao Kongsu D in the eye, or (Ii) Down-regulate or silence gene expression of eyeball Jiao Kongsu D. In some embodiments of the invention, the more specific location of the application above relative to the eyeball is the vitreous cavity. In some embodiments of the invention, the product for the above-described use comprises Jiao Kongsu D antibody or a pyroxsalen D inhibitor. In some embodiments of the invention, the Jiao Kongsu D antibody for use above comprises an antibody that inhibits Jiao Kongsu D. In some embodiments of the invention, the Jiao Kongsu D inhibitor for use above comprises Necrosulfonamide (NSA for short). In some embodiments of the invention, the product for use described above comprises a medicament, an agent or a vaccine. In some embodiments of the invention, the Jiao Kongsu D antibody is present in the product of the above application in an amount of 0.01 μg/μL、0.05 μg/μL、0.1 μg/μL、0.2 μg/μL、0.25 μg/μL、0.3 μg/μL、0.35 μg/μL、0.4 μg/μL、0.45 μg/μL、0.5 μg/μL、0.6 μg/μL、0.7 μg/μL、0.8 μg/μL、0.9 μg/μL、1.0 μg/μL、2.0 μg/μL、3.0 μg/μL、4.0 μg/μL or 5.0 μg/μl. In some embodiments of the invention, the NSA content in the product for the above application is 0.01 μm, 0.05 μm, 0.1 μm, 0.2 μm, 0.25 μm, 0.5 μm, 1.0 μm, 5.0 μm, 10 μm, 15 μm, 20 μm or 25 μm. In some embodiments of the present invention, the medicament for the above-described use comprises a pharmaceutical excipient selected from at least one of diluents, excipients, flavoring agents, sweeteners. The invention also provides a method for preventing or treating myopia, which comprises taking Jiao Kongsu D as a target point for preventing or treating myopia. In some embodiments of the invention, the above-described methods of preventing or treating myopia comprise administering the products of the above-described uses. In some embodiments of the invention, the above-described methods of preventing or treating myopia comprise administering a drug in a product for use as described above; The mode of administration may be instillation or injection. In some embodiments of the invention, the above method of preventing or treating myopia comprises intravitreal injection or parabulbar injection. In some embodiments of the invention, the prevention or treatment of myopia by the above-described applications or methods is achieved by reducing the myopic axis length and diopter or inhibiting the myopic axis length and diopter increase. The invention also provides a construction method of the myopia model, which comprises the construction based on the over-expression Jiao Kongsu D. In some embodiments of the invention, the above-described construction methods further